Tectonic Therapeutic, Inc. (TECX) stock
Close on Nov 11, 2026Market cap $429.30MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $429.30M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.87
- Dividend yield
- 0.00%
- Free cash flow yield
- -16.15%
Fundamentals
- Net income
- -$88.10M
- EPS, diluted
- -$4.63
- Free cash flow
- -$69.33M
- Book value per share
- $11.64
- Diluted shares
- 20M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $21.97
- Open
- $22.19
- Day's range
- $21.73 – $22.49
- Volume
- 134,217
- Average volume (20 days)
- 181,037
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.55
- 52-week range
- $16.77 – $39.53
- RSI (14 days)
- 52.0
- Volatility (1 year)
- 71.7%
- Relative volume
- 0.64×
- WACC
- 12.6%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TECX | S&P 500 | Difference | TECX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.9% | -2.4% | −3.5 pts | ||
| 3 months | -31.1% | -1.2% | −29.9 pts | ||
| Year to date | +5.3% | +12.3% | −7.0 pts | ||
| 1 year | +15.7% | +12.4% | +3.3 pts | ||
| 3 years | +33.6% | +78.8% | −45.2 pts | +10.1% | +21.4% |
| 5 years | -65.8% | +75.2% | −141.0 pts | -19.3% | +11.9% |
| 10 years | +18200.0% | +311.1% | +17888.9 pts | +68.4% | +15.2% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tectonic Therapeutic filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- Results
- Update
- Results
About Tectonic Therapeutic
Biological Products, (No Diagnostic Substances)
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors. Using its proprietary GEODe technology platform, the company creates biologics for conditions with substantial unmet medical needs. Its primary drug candidates include TX45, an Fc-relaxin fusion protein in clinical trials for pulmonary hypertension related to heart failure and interstitial lung disease, and TX2100, an antibody targeting the apelin receptor for the treatment of hereditary hemorrhagic telangiectasia. Because its candidates are in clinical and preclinical development, the company currently serves patient populations participating in clinical research rather than commercial customers.
Company profile, executives and historyTectonic Therapeutic stock: common questions
What is Tectonic Therapeutic's stock price?
TECX closed at $21.96 on Nov 11, 2026, down 0.05% on the day. Over the past 52 weeks it traded between $16.77 and $39.53.
What is Tectonic Therapeutic's market cap?
Tectonic Therapeutic was worth $429.30M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TECX's P/E ratio?
Tectonic Therapeutic lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.63), so it has no meaningful P/E ratio.
Does Tectonic Therapeutic pay a dividend?
No. Tectonic Therapeutic has not paid a cash dividend over the last twelve months.
When does Tectonic Therapeutic report earnings next?
Tectonic Therapeutic's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has TECX stock performed over the past year?
Including dividends, TECX returned +15.7% over the past year, against +12.4% for the S&P 500.
How many TECX shares are sold short?
2M shares were sold short at the latest FINRA report, 21.23% of the float, or 13.7 days of average trading volume.
Who are Tectonic Therapeutic's competitors?
Companies most similar to Tectonic Therapeutic by business, industry and size include RLAY, TNYA, ZURA, SRRK, SLDB.
See a number that looks wrong?